Soleno Therapeutics (SLNO) posts Q4 net revenue of USD 90–92 million and FY25 net revenue of USD 189–191 million
I'm PortAI, I can summarize articles.
Soleno Therapeutics Inc. reported preliminary financial results for Q4 and FY25, with expected net revenue of USD 90–92 million for Q4 and USD 189–191 million for FY25. The company achieved profitability and positive cash flow, with year-end cash and equivalents around USD 500 million after a USD 100 million share repurchase. Final audited results will be released in February 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments